AHA 2023 is a new PCSK9 inhibitor that reduces LDL with three monthly doses.

Published Date: 17 Nov 2023

AHA 2023 conference attendees recently witnessed the presentation of the REMAIN-2 trial results, which demonstrated that Recaticimab is a novel long-acting PCSK9 inhibitor.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Potential targets for treating the most common type of liver cancer in children have been identified by a collaborative study.

2.

Study identifies new approach to protect the brain during radiation therapy

3.

While most cancer screenings won't prolong lives, there are still good reasons to continue screening.

4.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

5.

Radiation therapy for patients with breast cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot